argenex SE $ARGX Shares Bought by Amundi

Key Points

• Amundi increased its argenx stake by 44.6% in the first quarter, owning 61,433 shares valued at approximately $44.9 million. Institutional investors and hedge funds collectively own 60.32% of the company.
• Analysts remain broadly positive, with argenx receiving a “Moderate Buy” consensus rating and an average price target of $1,056.89; several firms recently raised their targets to between $1,025 and $1,185.
• argenx reported quarterly earnings of $7.32 per share, exceeding the $5.86 consensus estimate, while revenue of $1.54 billion also topped expectations of $1.45 billion.

Amundi grew its holdings in argenex SE (NASDAQ:ARGX - Free Report) by 44.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 61,433 shares of the company's stock after acquiring an additional 18,948 shares during the quarter. Amundi owned 0.10% of argenex worth $44,861,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Oppenheimer & Co. Inc. lifted its position in argenex by 2.8% during the 4th quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company's stock worth $372,000 after acquiring an additional 12 shares during the period. Valeo Financial Advisors LLC lifted its holdings in shares of argenex by 0.9% during the fourth quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company's stock worth $1,153,000 after purchasing an additional 12 shares during the period. CI Investments Inc. lifted its holdings in shares of argenex by 2.6% during the fourth quarter. CI Investments Inc. now owns 469 shares of the company's stock worth $394,000 after purchasing an additional 12 shares during the period. Allworth Financial LP boosted its position in argenex by 12.7% in the fourth quarter. Allworth Financial LP now owns 115 shares of the company's stock valued at $97,000 after buying an additional 13 shares during the last quarter. Finally, WPG Advisers LLC increased its holdings in argenex by 17.8% in the 1st quarter. WPG Advisers LLC now owns 86 shares of the company's stock worth $63,000 after buying an additional 13 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have commented on the stock. Royal Bank Of Canada lifted their price objective on shares of argenex from $945.00 to $1,025.00 and gave the company an "outperform" rating in a research note on Friday, July 24th. Guggenheim raised their target price on shares of argenex from $1,135.00 to $1,185.00 and gave the stock a "buy" rating in a report on Friday, July 24th. Wedbush boosted their target price on shares of argenex from $1,000.00 to $1,050.00 and gave the company an "outperform" rating in a research report on Tuesday, July 28th. Robert W. Baird upped their price target on shares of argenex from $867.00 to $932.00 and gave the company a "neutral" rating in a report on Monday, July 27th. Finally, Citizens Jmp cut their price target on argenex from $944.00 to $932.00 and set a "market outperform" rating on the stock in a research report on Friday, July 24th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, argenex presently has an average rating of "Moderate Buy" and a consensus price target of $1,056.89.

argenex Price Performance

ARGX stock opened at $853.82 on Monday. argenex SE has a 52-week low of $631.47 and a 52-week high of $953.58. The firm has a market cap of $53.41 billion, a P/E ratio of 32.79, a PEG ratio of 1.08 and a beta of 0.46. The company's 50-day simple moving average is $875.66 and its 200-day simple moving average is $817.78.

argenex (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share for the quarter, beating the consensus estimate of $5.86 by $1.46. The firm had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.45 billion. argenex had a return on equity of 43.59% and a net margin of 32.19%. On average, analysts anticipate that argenex SE will post 28.05 earnings per share for the current fiscal year.

About argenex

argenx NASDAQ: ARGX is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx's research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company's lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source